HOME   |    PDF   |   


An update on diagnosis and therapeutics for type-2 diabetes mellitus



Shyamaladevi Babu*1, Ipsita Dash2, Ramya Badrachalam3, Madhan Krishnan1, Arjunkumar Panneerselvam4 & Sadhana Undru5



1Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam-603103, Tamil Nadu, India; 2Department of biochemistry, Saheed Laxman Nayak Medical College and Hospital, Pujariput, Koraput, Odisha- 764020; 3Department of Biochemistry, Sri Manakula Vinayagar Medical College & Hospital, Madagadipet, Kalitheerthalkuppam, Puducherry – 605107, Puducherry, India; 4Department of Pharmaceutics, Arulmigu Kalasalingam College of Pharmacy, Krishnankoil, Tamil Nadu, India; 5Department of Mental Health Nursing, Kims college of Nursing, KIMS & RF, Amalapuram, East Godavari district, Andhra Pradesh, India; *Corresponding author



Shyamaladevi Babu - E-mail: shyamdevi06@gmail.com; dr.shyamaladevi@care.edu.in 

Ipsita Dash - E-mail: ipsitadash71@gmail.com

Ramya Badrachalam - E-mail: drramya830@gmail.com

Madhan Krishnan - E-mail: kmadhan91@gmail.com; drmadhan@care.edu.in

Arjunkumar Panneerselvam - E-mail: arjunkumarpharm@gmail.com

Sadhana Undru – E-mail: sadhanaundru@gmail.com


Article Type

Research Article



Received March 1, 2023; Revised March 31, 2023; Accepted March 31, 2023, Published March 31, 2023



Type-2 Diabetes mellitus is a common metabolic disorder. It is combined with co-morbidities, such as obesity, hyperlipidemia, hypertension and cardiovascular disease which taken together, comprise the ‘Metabolic Syndrome’. This disease causes crucial morbidity and mortality at considerable expense to patients, their families and society. Different categories of drugs such as insulin secretagogues, insulin sensitizers, alpha-glucosidase inhibitors, GLP-1 agonists, DPP4 inhibitors, dual PPAR agonists and others are used for its management. Therefore, it is of interest to highlight the recent advances in diagnosis and therapeutics used in the treatment of type-2 diabetes mellitus. The classical and online-literature were used to compile data for this study. This includes the electronic search engine such as Scopus, Google Scholar, Sci Finder, PubMed and Web of Science. Data shows that there are different families of oral and injectable drugs at hand for the treatment of T2DM. Hence, we need to develop a novel, safety and effective agents that will improve the quality of life of T2DM patients, considering effectiveness and durability of lowering blood Glucose, risk of hypoglycemia and diabetes complications.



Type 2 diabetes mellitus; Diagnosis; Oral drugs; Insulin Secretagogues; Insulin sensitizer and dipeptidyl peptidase-4 inhibitors



     Babu et al. Bioinformation 19(3): 295-298 (2023)


Edited by

P Kangueane






Biomedical Informatics



This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.